C
NTLA icon

Covestor’s Intellia Therapeutics NTLA Stock Holding History

Covestor’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10K Buy
619
+30
+5% +$420 0.01% 1611
2026
Q1 		$8K Sell
589
-478
-45% -$6.09K 0.01% 1585
2025
Q4 		$10K Hold
1,067
– – 0.01% 1584
2025
Q3 		$18K Sell
1,067
-2
-0.2% -$25 0.01% 1314
2025
Q2 		$10K Sell
1,069
-3
-0.3% -$25 0.01% 1602
2025
Q1 		$8K Buy
1,072
+701
+189% +$7.08K 0.01% 1630
2024
Q4 		$4K Buy
371
+1
+0.3% +$16 ﹤0.01% 1765
2024
Q3 		$8K Hold
370
– – 0.01% 1664
2024
Q2 		$8K Sell
370
-7
-2% -$167 0.01% 1679
2024
Q1 		$10K Buy
377
+185
+96% +$5.14K 0.01% 1597
2023
Q4 		$6K Hold
192
– – ﹤0.01% 1753
2023
Q3 		$6K Sell
192
-1
-0.5% -$39 ﹤0.01% 1688
2023
Q2 		$8K Sell
193
-1
-0.5% -$41 0.01% 1586
2023
Q1 		$7K Buy
194
+5
+3% +$196 0.01% 1476
2022
Q4 		$7K Hold
189
– – 0.01% 1478
2022
Q3 		$11K Sell
189
-1
-0.5% -$62 0.01% 1229
2022
Q2 		$10K Buy
190
+108
+132% +$5.48K 0.01% 1220
2022
Q1 		$6K Buy
82
+36
+78% +$3.05K ﹤0.01% 1454
2021
Q4 		$6K Buy
+46
New +$5.76K 0.01% 1242

Other funds holding NTLA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Covestor's NTLA Position: Q2 2026 in Review

Covestor increased its Intellia Therapeutics (NTLA) stake by 5.1% in Q2 2026, buying an estimated $420 and bringing the position to 619 shares worth $10K. The position accounts for 0.01% of the portfolio, ranked #1611.

Covestor first reported a position in NTLA in Q4 2021 and has held it in 19 quarters since. The position peaked at $18K in Q3 2025. 231 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Covestor held 619 shares of Intellia Therapeutics worth $10K as of Q2 2026.
  • Covestor bought 30 Intellia Therapeutics shares in Q2 2026, an estimated $420.
  • Intellia Therapeutics made up 0.01% of Covestor's portfolio in Q2 2026, its #1611 holding.
  • Covestor first reported a position in Intellia Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • Covestor's Intellia Therapeutics position peaked at $18K in Q3 2025.
  • 231 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.